Healthcare products company West Pharmaceutical Services (NYSE: WST) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 9.2% year on year to $766.5 million. The company’s full-year revenue guidance of $3.05 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $1.84 per share was 22% above analysts’ consensus estimates.

Is now the time to buy WST? Find out in our full research report (it’s free).

StockStory’s Take

West Pharmaceutical Services delivered a quarter that outperformed Wall Street’s expectations, reflecting renewed strength in its core high-value product (HVP) components. Management attributed the results primarily to robust demand for GLP-1 elastomer products, ongoing conversions to HVP driven by regulatory upgrades, and the normalization of customer ordering patterns. CEO Eric Green highlighted that the company’s proprietary products segment saw particularly solid growth, with HVP components increasing 11.3% as West leveraged its pandemic-era investments to meet rising demand. Green explained, “Our improved performance was concentrated in our higher-margin businesses, which drove favorable margin expansion in the quarter.”

Looking ahead, West Pharmaceutical Services’ raised full-year guidance is built on expectations of continued HVP growth, further project wins related to Annex-1 regulatory requirements, and strengthening demand in biologics. Management anticipates that ongoing capacity expansion, particularly in Europe, and operational improvements will support higher output and margin resilience. CFO Bernard Birkett cautioned about potential volatility from tariffs, but noted, “We are utilizing every available mitigation lever to offset this impact.” The company remains focused on optimizing its global manufacturing network and expects multi-year growth opportunities as more customers upgrade to HVP components.

Key Insights from Management’s Remarks

Management cited accelerated adoption of high-value products, regulatory-driven upgrades, and operational progress as the main drivers behind both the strong quarterly results and the improved outlook.

• GLP-1 product surge: The demand for elastomer components used in GLP-1 therapies (drugs for obesity and diabetes) was a key growth driver, now representing 8% of total company revenue. CEO Eric Green noted that West was able to respond quickly to increased orders due to capacity investments made during the pandemic.

• Annex-1 regulatory upgrades: West saw a rising number of projects related to Annex-1, a regulatory standard requiring higher quality injectable components. The company now has 370 ongoing Annex-1 upgrade projects, up from 340 last quarter. Management expects this to deliver multi-year revenue growth, as these projects take 12 to 18 months to complete and lead to higher-margin product sales.

• Biologics and generics normalization: The biologics market unit delivered high single-digit organic sales growth, while generics showed signs of recovery. Management observed that destocking effects in generics are lessening, and ordering patterns are returning to normal, positioning both segments for improved performance.

• Operational improvements and capacity expansion: West is addressing production constraints in a key European HVP plant by ramping up hiring and training. These efforts are expected to improve output and asset utilization over the coming quarters.

• SmartDose automation progress: In the delivery devices business, a new automated production line for the SmartDose patch injector is scheduled to be introduced in early 2026. Management believes this will improve device economics and streamline manufacturing, although margin specifics were not disclosed.

Drivers of Future Performance

West expects growth to be driven by sustained demand for HVP components, regulatory upgrades, and expanding biologics adoption, while monitoring tariff risks and capacity constraints.

• Continued HVP component expansion: Management projects that HVP components will grow at a mid- to high single-digit rate for the year, underpinned by customer demand in GLP-1 therapies, biologics, and Annex-1 upgrades. West is leveraging its existing manufacturing network to meet this expected demand, but notes that some labor constraints at European plants could impact ramp-up speed.

• Annex-1 pipeline and project timing: The company sees a multi-year opportunity from the Annex-1 regulatory shift, with 370 projects in progress and more expected. These upgrades typically require over a year to commercialize, suggesting a steady pipeline of higher-margin business as customers transition from standard to high-value products.

• Tariff and operational risk mitigation: Management is closely monitoring the evolving tariff landscape, estimating a $15–20 million impact this year but emphasizing ongoing efforts to optimize plant locations, validate products across geographies, and pass through cost impacts to customers when possible. Any major changes in tariff policy could alter the company’s cost structure and outlook.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) the pace at which Annex-1 upgrade projects convert into commercial revenue, (2) whether the company can resolve labor constraints and expand production output at its European HVP plants, and (3) the resilience of biologics and GLP-1 demand amidst shifting healthcare trends. Developments in tariff policy and the successful ramp-up of SmartDose automation will also be important indicators of execution.

West Pharmaceutical Services currently trades at $278.50, up from $227.34 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.